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ABSTRACT: Hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels are membrane proteins encoded by
four genes (HCN1−4) and widely distributed in the central
and peripheral nervous system and in the heart. HCN
channels are involved in several physiological functions,
including the generation of rhythmic activity, and are
considered important drug targets if compounds with isoform
selectivity are developed. At present, however, few compounds
are known, which are able to discriminate among HCN channel isoforms. The inclusion of the three-methylene chain of
zatebradine into a cyclohexane ring gave a compound (3a) showing a 5-fold preference for HCN4 channels, and ability to
selectively modulate Ih in diﬀerent tissues. Compound 3a has been tested for its ability to reduce Ih and to interact with other
ion channels in the heart and the central nervous system. Its preference for HCN4 channels makes this compound useful to
elucidate the contribution of this isoform in the physiological and pathological processes involving hyperpolarization-activated
current.
KEYWORDS: Hyperpolarization-activated current, HCN channels, isoform selectivity, phenylalkylamines, zatebradine analogues,
rigid analogues
Hyperpolarization-activated cyclic nucleotide-gated(HCN) channels are members of the superfamilies of
voltage-dependent K+ (Kv) and cyclic nucleotide-gated (CNG)
channels. The architecture of these proteins resembles that of
voltage-gated potassium channels, showing a tetrameric
arrangement, each subunit being composed of six trans-
membrane domains including the voltage sensor S4, and a pore
loop between S5 and S6. At variance with Kv channels, the C-
terminal intracellular portion harbors a Cyclic Nucleotide
Binding Domain (CNBD). HCN channels carry a mixed Na+/
K+ current known as hyperpolarization-activated current (Ih),
are activated at hyperpolarizing voltages, and are modulated by
cyclic nucleotides (cAMP, cGMP, and others). Four isoforms
have been cloned (HCN1−4), diﬀering in localization and
biophysical properties.1−3
HCN channels are involved in various physiological
processes in the central and peripheral nervous systems and
in non-neuronal districts.1 For instance, HCN channels control
heart pace in the sino-atrial node (SAN), where HCN4 is the
most abundant isoform.4 In the central nervous system (CNS),
HCN channels regulate several functions, among which are
intrinsic excitability and rhythmogenesis. All four isoforms are
expressed, to diﬀerent extent and with diﬀerent distribution:
HCN1 and HCN2 are more widely distributed than HCN4,
which is mainly located in the thalamus.5 In the retina, where
HCN channels shape the light response, all four isoform are
expressed.6 In DRG, HCN1 and HCN2 are the most abundant
isoforms.7
HCN channels can be considered important drug targets for
cardiac pathologies and neurological diseases such as pain and
epilepsy,8,9 but the modulation of these channels has been
exploited so far only at the cardiac level. Ivabradine (Figure 1),
the only drug developed as a speciﬁc HCN channel blocker,
has been approved as a bradycardic agent in chronic stable
angina pectoris and to reduce hospitalization from worsening
heart failure.10,11 In addition, several lines of evidence have
suggested a role of HCN channels in pain perception and in
epilepsy.9,12−14 Indeed, ivabradine is able to attenuate
neuropathic and inﬂammatory pain15,16 and to increase the
threshold for maximal electroshock-induced seizures.17 How-
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ever, although ivabradine is well tolerated, its use for new
therapeutic applications may be restricted due to its lack of
selectivity since it blocks the four human HCN isoforms with
similar potency.18 Several clinically used drugs have been
reported to modulate Ih,
19 with few of them showing some
isoform selectivity, such as the anesthetic propofol for HCN120
or the anticonvulsant gabapentin for HCN4.21 However, these
molecules are not speciﬁc for HCN channels and interact with
other targets, while isoform-selective inhibitors could have a
safer pharmacological proﬁle due to the reduction of side
eﬀects.
Recently some of us have described the design, synthesis,
and characterization of phenylalkylamines endowed with
isoform preference or selectivity (Figure 1). In HEK 293
cells stably expressing homomeric HCN1, HCN2, and HCN4
channels, MEL57A (1) selectively inhibited the HCN1
isoform.22,23 Importantly, this selectivity was also maintained
in native tissues, where the channels may exist in the
heteromeric form. Compound 1 was able to reduce Ih in
DRG neurons at doses that did not inﬂuence heart rate;23
accordingly, 1 was eﬀective in reducing hyperalgesia and
allodynia in oxaliplatin-treated rats without cardiac eﬀects.24
Compound 2 (MEL55A) is an example of isoform-preferring
compound since it was shown to preferentially block HCN1
and HCN2 over HCN4;22 as its dimeric analogue 1, it was able
to relieve chemotherapy-induced neuropathic pain.25 In this
Letter we describe the design, synthesis, and characterization
of 3a (EC18),23 a phenylalkylamine showing preference for
HCN4 channels, and its usefulness to evaluate the physio-
logical role of this isoform.
Compound 3a (EC18) represents a rigid analogue of
zatebradine (Figure 1), the ﬁrst “speciﬁc bradycardic agent”
that entered clinical trials.19 The inclusion of the three-
methylene chain into a cyclohexane ring sharply reduced
zatebradine’s ﬂexibility, as 3a is able to adopt diﬀerent
conformations only in the phenethyl moiety. By this way it
was envisaged that some selectivity could be obtained; a similar
modiﬁcation made on verapamil, a structural analogue of
zatebradine, caused a separation of vasodilator and cardiac
depressant activities.26 A small set of cyclohexane derivatives
(3a−f, see structure in Scheme 1 and Table 1), characterized
by diﬀerent spacers between the basic nitrogen and the
dimethoxyphenyl ring, was designed and prepared. In addition,
we thought it would be important to also synthesize 3g, the
unsaturated analogue of 3a, since the presence of double bonds
gave interesting properties to 1 and 2.
The synthesis of compounds 3a−g was performed as shown
in Scheme 1. Following the procedure reported by Allan,27
methyl cyclohex-3-ene-1-carboxylate was reacted ﬁrst with N-
bromosuccinimide and then with the potassium salt of 7,8-
dimethoxy-2,3-dihydro-1H-3-benzazepin-2-one,28 giving 4,
which was hydrogenated on Pd/C yielding ester 5. This
preparation was performed several times, obtaining 5 with
similar yields (20−25%) and as mixtures of isomers, the most
abundant one being the cis ester (85−95%), which was
Figure 1. Structure of ivabradine, zatebradine, and analogues 1, 2, and
3a endowed with isoform preference or selectivity.
Scheme 1. Synthesis of Compounds 3a−ga
aReagents and conditions: (a) (1) NBS, AIBN, CCl4, heating; (2) t-
BuOK, 7,8-dimethoxy-2,3-dihydro-1H-3-benzazepin-2-one; (b) H2/
Pd/C; (c) chromatographic separation; (d) NaOH; (e) DPPA,
toluene, then HCl; (f) (1) SOCl2, (2) NaN3, acetone; (3) Δ, toluene;
(4) HCl; (g) arylalkyl halides 8a−e, Et3N; (h) CH2O, HCOOH. Ar =
3,4-dimethoxyphenyl. X = (CH2)2 (a); CH2 (b); (CH2)3 (c);
(CH2)2O (d); CH2CHCH (e); 3f, R = 3,4-dimethoxybenzyl, X =
CH2.
Table 1. Percentage of Reduction of Ih at −80 mV after
Application of Drugs at the Concentration of 5 μM on
Human HCN4 Channel Expressed in HEK 293 Cellsa
N R1 R2 Ih reduction (%)
3a (EC18)b Me −CH2CH2Ar 59 ± 14 (n = 5)
(+)-3a Me −CH2CH2Ar 46 ± 7.7 (n = 3)
(−)-3a Me −CH2CH2Ar 45 ± 20.1 (n = 4)
3bb Me −CH2Ar 21 ± 12 (n = 6)
3cb Me −CH2CH2CH2Ar 47 ± 16.1 (n = 4)
3db Me −CH2CH2OAr 48 ± 6.9 (n = 7)
3eb Me −CH2CHCHAr 64 ± 8.0 (n = 4)
3fb CH2Ar −CH2Ar ∼4 (n = 4)
3gc Me −CH2CH2Ar 30 ± 11.6 (n = 4)
zatebradine 59 ± 19 (n = 5)d
aValues are normalized to control and represent the mean ± SD of
3−7 experiments. bSingle bond. cDouble bond on both rings.
dObtained with a 10 μM concentration. Ar = 3,4-dimethoxyphenyl.
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separated from the trans one by means of chromatography.
The cis−trans conﬁguration was assessed by means of NMR, as
previously done for other cyclohexane derivatives:26 the width
of the peak related to the cyclohexyl proton in position 1 was
wider for the cis isomer (H axial) with respect to the trans one
(H equatorial). The cis conﬁguration was then conﬁrmed by a
NOESY experiment. Alkaline hydrolysis of cis-5 gave the
corresponding acid 6, which was transformed into amine 7
through Curtius rearrangement of the acyl azide. This step was
performed in two diﬀerent ways. Treatment of the acid with
DPPA (diphenyl phosphoryl azide) in toluene (method A),
followed by acid hydrolysis of the intermediate isocyanate,
gave 7 in about 50% yield. Alternatively, the acyl azide was
prepared by reaction of the acyl chloride with sodium azide;
heating in toluene and subsequent acid hydrolysis gave the
amine 7 in slightly higher yields (method B, 60% yield).
Reaction of 7 with the suitable arylalkyl halide (8a−e) gave
secondary amines 9a−e, which were transformed into N-
methyl-derivatives 3a−e by reaction with formaldehyde and
formic acid; when using 3,4-dimethoxybenzyl bromide, some
amount (4%) of double addition product 3f was obtained.
Compound 4 was transformed into 3g using the same reaction
sequence but avoiding catalytic hydrogenation.
As a preliminary screening, the compounds were tested at a
5 μM concentration to check their ability to block h-current on
human HCN4 stably expressed in HEK 293 cells, at voltages
(−80 mV) mimicking physiological membrane potential
(Table 1). Under these conditions all the compounds were
able to inhibit h-current, the majority of the compounds
producing about 50% reduction. Representative traces are
reported in Figure S1. The benzyl analogue 3b and the
unsaturated derivative 3g were much less active, the extent of
reduction being smaller (21% and 30%, respectively); the
dibenzyl compound 3f was almost inactive. To understand the
importance of chirality, the enantiomers of 3a were separated
by means of HPLC (Figures S2 and S3), but no
enantioselectivity was observed (Table 1). Although small,
this set of compounds can suggest some structure−activity
relationships: the insertion of two double bonds in the
azepinone and cyclohexane rings is not productive, as well as
the increase in size of both R1 and R2 substituents. On the
contrary, the length and type of the spacer between the basic N
atom and the dimethoxyphenyl moiety can be varied, still
maintaining good potency.
Owing to its similarity with zatebradine, compound 3a
(EC18) was selected for further characterization, which has
been partially disclosed previously.23 This compound was
tested on the homomeric HCN1, HCN2, and HCN4 channels
expressed in HEK293 cells: it showed a 5-fold preference for
HCN4 (EC50 3.98 ± 1.16 μM) over HCN1 (EC50 21 ± 3.98
μM) and HCN2 (EC50 19.35 ± 4.48 μM). Consistently with
its good activity on HCN4, in guinea pig SAN 10 μM 3a
reduced Ih by ∼67% at −120 mV, and on dog cardiac Purkinje
ﬁbers it reduced the amplitude and slowed the slope of
diastolic depolarization phase.23 Moreover, on guinea-pig
spontaneously beating isolated atria, it produced a negative
chronotropic eﬀect (IC50 9.9 ± 5.5 μM), with potency
comparable to zatebradine (IC50 13.7 ± 8.7 μM).
29
In line with its lower activity on HCN1 and HCN2 channels,
on mouse DRG neurons 3a did not aﬀect Ih conductance, at a
physiologically relevant voltage, up to a concentration of 100
μM.23 Indeed, 3a was unable to reduce hypersensitivity when
tested in a mouse model of oxaliplatin-induced neuropathy, a
ﬁnding in line with the low expression of this isoform in DRG
neurons.25
EC18 (3a) represents the ﬁrst HCN4-preferring compound,
discovered in a project aimed to ﬁnd zatebradine analogues
endowed with isoform selectivity.22,23 In fact, when tested on a
recombinant HCN4 channel, EC18 showed a potency in the
same range as ivabradine, but a 5-fold preference for this
isoform with respect to HCN1 and HCN2, while ivabradine
reduced h-current with the same potency on the three
isoforms.18 Notably, the preference obtained at recombinant
channels is maintained in native tissues, thus making 3a a tool
to study the individual function of HCN4 channels in cardiac
cells and neurons. Other HCN4-selective/preferring com-
pounds have been described, such as the already mentioned
gabapentin21 and amiodarone.30 However, both compounds
have been developed for interaction with other targets, and
their multi-ion channels blocking properties can obscure
selectivity for HCN4 channels, even if the activity on HCN4
channel may contribute to their pharmacological eﬀect.
Although a complete characterization of 3a on other
channels or receptors has not been done yet, some experiments
on cardiac tissue suggest that 3a also interacts with other ion
channels. In fact, in dog ventricular papillary muscle at a
stimulation cycle length of 1000 ms, 3a (10 μM) signiﬁcantly
and strongly inhibited the Vmax and increased conduction time
(Figure 2, Table S1). Compound 3a moderately shortened the
action potential (AP) duration at 1 μM, then prolonged the
action potential duration at 10 μM.
EC18 was found to have a cardiac electrophysiological
proﬁle similar to that of ivabradine in view of the ability to
inhibit Vmax and to prolong repolarization at 10 μM
concentration.31 The AP duration shortening exerted by 1
μM EC18 is probably attributable to Na+ channel blockade.
The inhibitory eﬀect of EC18 on Na+ channels might still exist
at 10 μM, but regarding the eﬀect of EC18 on the
repolarization, the simultaneous K+ channel blockade could
outweigh this AP shortening eﬀect. Further studies are
required for establishing the degree of the K+ current inhibition
by EC18 in cardiomyocytes. Ivabradine, in addition to blocking
Figure 2. Eﬀect of 3a (EC18) on the action potential repolarization in
dog papillary muscle (n = 5) at stimulation cycle length of 1000 ms
(representative action potential waveform recordings originate from
the same preparation).
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the pacemaker current, was found able to inhibit hERG
channels with a potency that is similar to that reported for
HCN4 (see ref 1 and references therein). EC18 might have a
similar action.
EC18 can be useful to study HCN channels not only in
heart but also in the CNS. In the thalamus, a brain region
mainly expressing HCN4 and HCN2 channels,33,34 compound
3a has been used to understand the contribution of the HCN4
isoform to Ih in small and large interneurons of the dorsal part
of the lateral geniculate nucleus, which are classiﬁed based on
diﬀerences in Ih current density. In these GABAergic neurons
30 μM 3a reduced Ih by about 31.4 ± 5.2%.
35 As a further
characterization, in this work we report the eﬀect of 3a in
thalamocortical relay (TC) neurons of the ventrobasal
thalamic complex (VB), which belong to the principal thalamic
neurons. Here, compound 3a revealed stronger eﬀects with 30
μM blocking 91.3 ± 0.7% (n = 2) of Ih in these cells (Figure
3A). The construction of a dose−response relationship
pointed to an EC50 value of around 11 μM (Figure 3B).
These data suggest that in TC neurons Ih is mainly mediated
by HCN4 or HCN2/4 heteromers and indicate that
compound 3a is a valuable tool for analyzing the cell type-
speciﬁc properties and function of HCN channels in native
neurons.
An eﬀect on K+ current was found also in VB TC neurons
(Figure 4). When K+ outward currents were induced by step
depolarizations (Figure 4A, lower inset) 10 μM 3a blocked
14.5 ± 2.2% (n = 8; Figure 4B) of the late component while
leaving the early transient current unaﬀected. These ﬁndings
indicate that compound 3a has selective eﬀects on diﬀerent
types of voltage-dependent K+ channels, blocking slow delayed
rectiﬁer channels (Figure 4A upper inset) but not aﬀecting K+
channels carrying A-type current in TC neurons.32,36
The data reported in this Letter suggest that compound 3a is
a valuable tool to study HCN channel isoforms in the CNS
and in heart, useful to clarify the contribution of diﬀerent
HCN isoforms in mediating Ih. As well as for compounds 1
and 2, the ability of 3a to discriminate among HCN channel
isoforms is an advantage with respect to compounds such as
ZD7288 or ivabradine, which are commonly used to block Ih
but are not isoform-selective and, as well as 3a, nor absolutely
speciﬁc for HCN channels.37,38
In conclusion, a compound has been discovered, 3a (EC18),
showing some selectivity for HCN4 channels, and able to
discriminate among HCN channel isoform in recombinant
systems and in native tissues. Even if 3a shows some activity on
Na+ and K+ currents, its HCN4 blocking properties make it a
valuable tool to study HCN4 channels in a physiological
environment or in pathologies, such as those of the CNS. In
particular, the HCN4-blocking activity in the thalamus opens
the way to test this compound in animal models of
neurological disorders; the results of these tests will be
presented in due time. Work is underway to improve potency
and selectivity of the lead compound.
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Figure 3. Eﬀect of compound 3a on Ih in thalamic neurons. (A)
Sample whole-cell patch clamp recordings showing the current
reduction in VB TC neurons in brain slices32 by diﬀerent 3a
concentrations (1, 10, and 30 μM as indicated). Ih in the presence
(red line) and absence (black lines) of 3a was elicited by standard
voltage protocols (see Supporting Information 1). Scale bars
represent 1 nA and 2 s. (B) Dose−response relationship of Ih
amplitude reduction. The EC50 value was estimated by ﬁtting a
sigmoidal function (red line) to the data points (see Supporting
Information 1).
Figure 4. Eﬀect of compound 3a on K+ outward currents in thalamic
neurons. (A) Families of outward currents evoked by standard voltage
protocols (see lower inset and Supporting Information 1) under
control conditions (black traces) and in the presence of 10 μM 3a
(red traces) following acute isolation.33 Late current components
(arrowhead) but not the early transient currents (arrow) were
aﬀected. The 3a-sensitive component is shown in the upper inset
(scale bars represent 200 ms and 500 pA). (B) Current−voltage
relationship of the late current component (see arrowhead in A).
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